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Abstract
Controlled Drug Substance Use in West Virginia: An investigation into Doctor Shopping, Pharmacy
Shopping, And Prescription Histories
Gretchen L. Peirce
One objective was to compare the proportion of doctor and pharmacy shoppers between living and
deceased users of controlled drug substances (CDS) in West Virginia. A second objective was to identify
factors that predict the odds a subject is classified as a shopper. A third objective was to determine
factors that predict the odds of dying from CDS use. A final objective was to identify factors that predict
the odds of deceased subjects not having verified prescriptions for CDS detected upon autopsy.
A secondary data research study was conducted. The Controlled Drug Substance Monitoring Program
and the Forensic Drug Database were used to identify subjects who were 18 years or older and used
Schedule II-IV controlled drug substances in the state of West Virginia from July, 1, 2005 to December
31, 2007.Bivariate analyses were used to compare living and deceased subjects for both doctor shopping
and pharmacy shopping. Logistic regression was conducted to predict the odds of doctor shopping,
pharmacy shopping, and of dying related to CDS use. Bivariate analyses were used to compare
decedents with versus without verified prescriptions for CDS detected upon autopsy. Logistic regression
was conducted to predict the odds that a decedent did not have verified prescriptions for all CDS
detected upon autopsy.
Approximately 25.36% of deceased subjects and 3.61% of living subjects were doctor shoppers.
Approximately 17.91% of deceased subjects and 1.31% of living subjects were pharmacy shoppers.
Furthermore, 7,778 subjects were considered both doctor and pharmacy shoppers (20.31% of doctor
shoppers were also pharmacy shoppers, and 55.83% of pharmacy shoppers were also doctor shoppers).
Age, number of different CDS dispensed, number of prescriptions dispensed, and number of pharmacies
visited significantly predicted the odds of being classified as a doctor shopper. Life status, age, number
of different CDS dispensed, number of prescriptions dispensed, and number of doctors visited
significantly predicted the odds of being classified as a pharmacy shopper. Age, number of different CDS
dispensed, number of prescriptions dispensed, and number of pharmacies visited significantly predicted
the odds of dying. Approximately 30% of decedents had a verified prescription for all their CDS detected
upon autopsy. Age, number of different CDS at autopsy, and gender significantly predicted the odds of
being classified as not having verified prescriptions for all CDS detected upon autopsy.
In conclusion, there is evidence of doctor shopping and pharmacy shopping for controlled drug
substances in West Virginia. Interventions by healthcare professionals are important because only a
third of decedents had a verifiable prescription for all their CDS detected upon autopsy. Pharmacists as
well as physicians may rely on a prescription monitoring program to identify shoppers. Healthcare
professionals should consider integrating prescription monitoring program information during delivery
of care, and evaluate its impact in preventing drug-induced and drug-related deaths.
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Chapter 1: Introduction

Chapter 1
Introduction

Background

Prescription drug abuse continues to be a problem in the United States.1-12 West Virginia has a
higher than average prescription drug abuse rate than the national average.7,12 Even though noncontrolled drug substances such as antidepressants are abused, the most commonly abused drugs are
controlled drug substances.1,4,8,11,13
Federal and state governments and professional associations have tried to prevent and reduce
prescription drug abuse through regulations and policies.14,15 To help reduce prescription drug abuse,
West Virginia implemented a controlled substance monitoring program in 1995.15 Even with this
program, prescription drug abuse rates in the state have continued to increase.7,12 Although a
controlled substance monitoring program can be a useful tool, evidence shows that only a fraction of
healthcare professionals use them.16
There are many different avenues to divert prescription drugs.17-23 Pharmacy shopping and
doctor shopping are avenues to prescription drug diversion which healthcare professionals can help to
reduce in daily practice, especially with the aid of controlled substance monitoring programs. Several
studies have investigated doctor shopping.7,13,24-27 One study in West Virginia examined patterns of
prescription drug abuse among those who died with a prescription drug detected upon autopsy and
found that approximately 21% of deaths were related to doctor shopping.7 There has been very little
research in the area of pharmacy shopping.26,28,29 Although, one study did find that the greater the
number of providers used, the number of pharmacies also increased based on data from the
Massachusetts Prescription Monitoring Program.29
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There has been much discussion for several decades about balancing the benefits of using
controlled drug substances and the risk of prescription drug abuse.14,15,17 Some argue that pain
management is undertreated in the United States, especially in those patients who have a substance
addiction,15 and should be treated with opioids and other controlled drug substances.23 Others argue
that there are too many regulations and potential repercussions such as litigation and criminal charges
that prevent proper prescribing of controlled drug substances to treat pain or other diseases.22
To the authors’ knowledge there has been no study to date that compared the use of controlled
drug substances in living patients to use in persons who died with controlled drugs detected upon
autopsy. The verification of prescriptions for drugs detected upon autopsy in decedents has been
studied in West Virginia using data that spanned a single year.7 Studies verifying prescriptions for
controlled drug substance use in decedents covering a longer time period are lacking.

Purpose of the Study
The study specifically examined the use of controlled drug substances in West Virginia, due to
the state’s high rate of prescription drug abuse.7,12 Data from the West Virginia Board of Pharmacy’s
Controlled Substance Monitoring Program and the Office of the Chief Medical Examiner’s Forensic Drug
Database were used to determine the prevalence of doctor shopping and pharmacy shopping related to
controlled drug substance use in West Virginia. The study provided evidence of doctor shopping and
pharmacy shopping in West Virginia by comparing controlled drug substance records of living versus
deceased subjects. The study also added to the literature by verifying presence of prescription records
for controlled drug substances detected upon autopsy in decedents over multiple years, as opposed to a
single year.7
The purpose of the study was to answer the overall question of what patterns are present
related to controlled drug substance use in West Virginia, specifically pharmacy and doctor shopping.
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The specific research questions that the study addressed include:
Research Question 1: What factors are significantly related to doctor shopping?
Research Question 2: What factors are significantly related to pharmacy shopping?
Research Question 3: What factors are significantly related to the odds of dying with controlled drug
substance use?
Research Question 4: What factors are significantly related to controlled drug substance prescription
verification?

Significance of the Study
There have been few studies examining doctor shopping, and none comparing doctor shopping
in living subjects who are using controlled drug substances with subjects who have died with a
controlled substance detected upon autopsy. Very little has been studied with regard to pharmacy
shopping in persons who died. The study will compare pharmacy and doctor shopping between living
and deceased subjects. The findings generated from this research will raise awareness of issues
associated with prescribing and dispensing controlled drug substances, and consider need for
interventions to modify doctor and pharmacy shopping behaviors for controlled drug substances.

Study Objectives
The study objectives were to compare living and deceased subjects for doctor shopping and
pharmacy shopping. Another objective was to identify factors that significantly predict the odds of
dying from controlled drug substance use. Finally, the last objective was to identify significant factors
related to having prescriptions for controlled drug substances among decedents who had a controlled
drug substance detected on autopsy.
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Objective I: Doctor Shopping
Objective 1: To identify significant factors associated with doctor shopping.
Null Hypothesis 1a: There is no significant difference between the proportion of subjects who doctor
shop and those who do not based on life status.
Null Hypothesis 1b: There is no significant difference between the proportion of subjects who doctor
shop who are living versus deceased by age group, pharmacy shopping, number of different controlled
drug substances dispensed and number of prescriptions dispensed.
Null Hypothesis 1c: There are no significant factors associated with doctor shopping.

Objective II: Pharmacy Shopping

Objective 2: To identify significant factors associated with pharmacy shopping.
Null Hypothesis 2a: There is no significant difference between the proportion of subjects who pharmacy
shop and those who do not based on life status.
Null Hypothesis 2b: There is no significant difference between the proportion of subjects who pharmacy
shop who are living versus deceased by age group, doctor shopping, number of different controlled drug
substances dispensed and number of prescriptions dispensed.
Null Hypothesis 2c: There are no significant factors associated with pharmacy shopping.

Objective III: Controlled Drug Substance Mortality Odds
Objective 3: To identify significant factors associated with the odds of dying from use of controlled drug
substances.
Null Hypothesis 3: There are no significant factors associated with the odds of dying related to the use of
controlled drug substances.
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Objective IV: Controlled Drug Substance Prescription Verification

Objective 4: To identify significant factors associated with controlled drug substance prescription
verification (i.e., having verified prescriptions for the controlled drug substances detected upon
autopsy).
Null Hypothesis 4a: There is no significant difference between the proportion of decedents between the
verified group and the non-verified group based on age group, number of different controlled drug
substances (autopsy), and gender.
Null Hypothesis 4b: There are no significant factors associated with controlled drug substance
prescription verification.

Study Assumptions
The primary assumption of the study is that living and deceased groups have similar drug use
patterns. It is unknown if the subjects are getting controlled drug substances from another source even
though they have at least one verified prescription for a controlled drug substance identified by the
Controlled Substance Monitoring Program. It is also assumed that living and deceased groups have
similar use of other prescription medications (e.g., over-the-counter medications and illicit drug use)
because only controlled drug substance use is captured in the Controlled Substance Monitoring
Program, the only source used in the study for objectives 1-3.
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Prescription Drug Abuse

Studies have examined prescription drug abuse through the use of databases1,3-5,7,13 and by
surveys of patients2,6 and community pharmacists.30 An Australian study of heroin decedents aged 1524 found that poly-drug use was detected in 90% of the cases and of these 80% involved prescription
drugs, predominately benzodiazepines and opioids.13 A study by McCabe and colleagues showed that
the past year prevalence of prescription sedative abuse, sedative dependence, opioid abuse, and opioid
dependence increased from 1991-1992 to 2001-2002.1 Through the National Household Survey from
1991-1993, it was found that nearly 1.3 million Americans experienced a problem with prescription drug
use that signified a psychological dependence with heavy daily use.3 Maxwell compiled several reports
from multiple data sources into one document on the growing abuse of prescription drugs.11 According
to the 2002 National Survey on Drug Use and Health (NSDUH) approximately 29.6 million Americans
used pain relievers non-medically in their lifetime. By 2005 the number increased to 32.7 million
Americans, of whom 18-25 year olds used more pain relievers, benzodiazepines, and muscle relaxants
than any other age group.11 The Drug Abuse Warning Network Medical Examiner Reports (DAWN ME),
in which only 6 states participated, showed that in 2003, 66-93% of drug-related deaths involved more
than one drug.11 The National Center for Health Statistics reported that opioid analgesic deaths
increased by 91% from 1991 to 2002.11 The National Forensic Laboratory Information System reported
that from 2001-2005 narcotics and benzodiazepines represented nearly 5% of all drugs analyzed.11
Paulozzi and colleagues found that unintentional drug death rates increased an average of 5.3% from
1979-1990 and 18.1% from 1990-2002.4 They found that opioid analgesics increased at a rate of 91.2%
from 1999-2002, while heroin and cocaine increased by 12.4% and 22.8%, respectively.4 From the
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National Center on Addiction and Substance Abuse (CASA) 2005 report there was a 14% increase in the
US population and a 94% increase in the abuse of controlled prescription drugs from 1992-2003.9 CASA
2005 reported that 15.1 million people admitted to abuse of prescription drugs.9 The Substance Abuse
and Mental Health Services Administration (SAMHSA) survey showed the highest increase in abuse was
with oxycodone.8 These research studies and reports provide evidence of a prescription abuse problem,
particularly poly-drug use and opioid abuse, in the United States.
According to the Office of National Drug Control Policy (ONDCP) and the National Survey on
Drug Use and Health, prescription drug abuse is one of the most serious public health threats in West
Virginia.12 An average of 5% of those aged 12 or older in West Virginia used pain relievers for
nonmedical purposes in 2005-2006.12 A 2006 study of overdose deaths in West Virginia found the
deaths to be primarily associated with non-medical use and diversion of pharmaceuticals, mostly opioid
analgesics.7 Opioid analgesics were taken by 93.2% of decedents with only 44.4% of them having been
prescribed these drugs.7
Risk factors have been identified for prescription drug abuse.2,3 A study of college students who
used prescriptions for non-medical purposes and illicit drugs found marijuana use correlated heavily
with non-medical use of prescription drugs, while being black and attending a commuter college were
negatively correlated with non-medical use of prescription drugs.2 The 1991-1993 National Health
Survey found that those at greater risk for a problem with prescription drugs were older adults, females,
those with poor/fair health, and daily alcohol drinkers.3 The 2002-2005 National Survey on Drug Use
and Health found that 4.8% of people 12 years and older had taken a prescription pain reliever nonmedically, of which males (especially those between 18 and 34 years) tended to have higher rates of
abuse.10 Those aged 18-25 years had the highest rate for both genders.10 A report from the DAWN ME
similarly found higher rates of opiate deaths in those aged 21-54 years by age and also in males.11 Of
those who abused prescription pain relievers for non-medical purposes, 57.7% used hydrocodone and
7
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21.7% used oxycodone.10 A study that surveyed patients with the Abuse Index found patients with
chronic non-cancer pain were more likely to misuse drugs.6 Chabal and colleagues found that 34% of
pain clinic patients met at least one of the criteria for abuse, and suggest a five point prescription opiate
abuse checklist that could be used in normal clinical interactions.31 Turk et al. found that pain behaviors
(i.e., behavioral manifestations of pain, distress, and suffering, as well as functional disability and
distress) were significant predictors of being prescribed opiates compared to patients who were not.32
Thus patients with these factors may be at greater risk for prescription drug abuse so healthcare
professionals should carefully monitor such patients when prescribing/dispensing controlled drug
substances. Identifying risk factors and behaviors is only one way healthcare professionals can prevent
prescription drug abuse. Discovering how and why patients divert or misuse prescription drugs would
add more insight on how to prevent prescription drug abuse.

Implications of Prescription Drug Abuse
Although the US makes up for only 4.6% of the world’s population, they consume 80% of the
global opioid supply and 99% of the global hydrocodone supply.33 Paulozzi and colleagues found that
the increase in opioid deaths followed the increase of sales for each type of opioid.4 Based on the DEA
Automation of Reports and Consolidated Orders System (ARCOS) report of prescription drug sales, sales
of oxycodone surpassed hydrocodone since 2000.11 Compton and Volkow highlighted a finding by Zacny
and colleagues (2003) that increases in problems were associated with increases in prescriptions
particularly for oxycodone, fentanyl, and morphine prescriptions.34 Hydrocodone/APAP was reported as
the number one prescribed drug from the RX List.17 According to Kuehn, the 2005 International
Narcotics Control Board reported a 60% increase in domestic use of hydrocodone in the US between
2002 and 2004.17 As prescriptions numbers increase there is a logical increase in the risk of abuse of
prescription drugs.
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The 1995 CASA report estimated $77.6 billion of healthcare and disability costs are related to
substance abuse.35 The 2004 DAWN ED report, as described by Maxwell, found that there were 1.3
million emergency department visits associated with drug misuse and abuse, with most involving
multiple drugs.11 Of those visits involving a single drug, 33% were opiates, 23% were benzodiazepines,
and 16% were muscle relaxants.11 Those aged 21-54 years had the highest rates of emergency
department visits.11 The Treatment Episode Dataset report, as given by Maxwell, found that between
1944 and 2004 opiates other than heroin increased from 14,197 to 60,017 with regard to the number of
patients admitted to treatment centers; these patients tended less likely to be male and a person of
color.11 Approximately 10% of US patients in treatment indicated their principle drug of abuse is a
prescription drug.36 Rice and colleagues estimated the total losses to the economy in 1988 related to
alcohol abuse, drug abuse, and mental illness were approximately $273.3 billion; $58.3 billion was
attributed to drug abuse alone, which most likely underestimates the true cost to society.37 McLellan et
al. reported that many expensive and disturbing social problems are associated with drug dependence.38
There were 4,100 arrests for drug abuse in West Virginia in 2006, along with 1,249 treatment admissions
for abuse of opiates other than heroin.12 These reports show the burden of increased utilization of
controlled substances, particularly opiates, on healthcare, societal and economic costs.
Prescription drug abuse does not just affect those abused and society; it has real implications for
physicians as well. Physicians face the dilemma of prescription drug abuse when treating illnesses that
may require controlled drug substances including pain management.14,15,17 Managing pain was
emphasized as the 5th vital sign.39 Opioids have an important role in the treatment of pain;15 however,
there is also evidence that opioids may not always be the best treatment.22 Pain should be treated
along with the use of clinical risk management tools to decrease abuse and diversion.40
Opioid abuse has made pain management even more complicated since there tends to be an
under-treatment of pain, especially in patients who abuse prescription drugs.15 Many states have
9
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regulations that prohibit physicians from prescribing controlled substances to individuals addicted to
controlled substances.41 Drug dependence has often been treated as an acute illness; however, it
causes changes in brain chemistry and function that lead to long-term effects.38 It is important that it be
treated and monitored as a chronic illness.38 Patients with pain should be treated for pain, although
heightened patient monitoring should be employed with termination of medication if they deviate from
the plan.23 However, heightened scrutiny on physicians’ prescribing may have an adverse effect on
patient care.23 Regulations should not impede the treatment of pain in addicts, but rather should strictly
manage treatment to prevent controlled drug substances from being abused.

Prescription Drug Regulations
Researchers and experts agree that appropriate pain management and prevention of
prescription drug diversion /abuse is a delicate balance.

14,15,17

It is often complicated by such things as

regulations and litigations which put pressure on physicians. Doctors may face litigation for failure to
treat or for under-treatment of pain,22,40 or criminal charges for patient abuse, addiction or death.22
Patients contribute to the problem since in one study, 28 out of 90 patients provided physicians with an
inaccurate history of controlled substance use.22 Of those that reported opioid use, 16 out of the 90
were under-reporters and 8 out of 42 patients taking a benzodiazepine under-reported the use of
benzodiazepines.22 Laws and regulations, triplicate prescriptions and prescription monitoring programs
have been used to offset the delicate balance in favor of appropriate use of prescription drugs for
patient management over prescription drug diversion/abuse.
From the early 19th century, physicians and regulators have been concerned over the abuse
potential of certain drugs such as narcotics.14,15 They created laws to help regulate the manufacturing
and distribution of these drugs.14,15 The Pure Food and Drugs Act of 1906 created the “dangerous” drugs
list which included habit forming substances.14 The Harrison Act of 1914 created a register of narcotic
distributers and in 1919 made it a legitimate professional practice .14 The Porter Act of 1929 established
10
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Narcotic Hospitals.14 The Narcotics Manufacturing Act of 1960 created a closed system of narcotics
manufacturing and distribution, licensed manufacturers, and established quotas for natural and
synthetic opiates.14 The Food Drug and Cosmetic Act of 1938 – 1951 created legend drugs, although
narcotics were still under the control of the Department’s Federal Bureau of Narcotics (FBN).14 Narcotic
regulation was important in the United States and worldwide.14 The 1961 Single Convention established
international control and a global standard and is still the lynchpin of narcotic regulatory arrangements
of present day.14 The Controlled Substance Act combined the Federal Bureau of Narcotics and the FDA
Bureau of Drug Abuse Control to form the Bureau of Narcotics and Dangerous Drugs, which controls
interstate commerce.14,40,42 The Drug Abuse Prevention and Control Act of 1970 consolidated more than
50 federal drug laws.42 The 1971 Psychotropic Convention was similar to the 1961 Single Convention,
which was under the same assumption that supply control provided the key to eliminating substance
abuse.14 In 1973 the Bureau of Narcotics and Dangerous Drugs created the Drug Enforcement Agency.
14

This is just a brief history of federal regulations to control prescription drug abuse through supply

channels such as manufacturing and distribution of narcotics.
Other laws and regulations have been directed specifically at healthcare providers, such as
educational requirements and surveillance tools. To best manage patients while minimizing drug misuse
or abuse, it is important that principles of pain management be incorporated into medical schools as
well as continuing education.17 West Virginia mandated a curriculum in pain management and palliative
care in its medical schools.40 The federal government included regulations for establishing prescription
monitoring programs to further provide information about possible drug abuse to law enforcement and
physicians.15

Prescription Monitoring Programs
Prescription monitoring programs (PMPs) have increased in number over the years. There were
10 in 1992 and 15 in 2002, which covered 47% of the population and 45% of the nation’s pharmacies.43
11
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There are currently 27 PMPs,44 covering 23 states in the country.45 The major problems associated with
PMPs are passing legislation to establish a PMP, creating the PMP and securing funding for the
program.44
Even though PMPs were developed to identify patterns of prescription drug abuse through
dispensing and have been a useful tool to reduce diversion,15 they are inadequate alone to reduce
prescription drug abuse. A survey of prescription monitoring program directors was conducted to
examine data captured by the programs, data sharing procedures, healthcare training, program goals
and evaluation efforts.45 Although most states collect Schedule II prescription data, there are states that
collect Schedules II-V while other states vary somewhere in between.15,45 Most pharmacies report data
to PMPs that varies from one hour to no more than a week after the prescription has been filled.45
The majority of PMPs were created with the goal to provide patients with better access to
opioids for pain management and to increase physician comfort in prescribing opioids, while reducing
abuse.45 Yet very few states use the data for epidemiological studies, to conduct evaluations of the
PMP, or to provide user guidelines.45 Only eight states reported developing educational programs based
on data collected through the PMP.45 Few states provide suspicious use information to physicians
proactively, while other states do not allow healthcare professionals to access information at all. Some
states only allow physicians to access data contained in the PMP, and some states only allow
information to be obtained upon request.15,45 Weissman and Johnson discussed four negative effects of
PMPs: 1) placing restrictions on physician practice; 2) affecting patient access to opioids; 3) stigmatizing
patients; and 4) negatively impacting physician perceptions of regulations, resulting in modified medical
practices.46 There is also a lack of communication between states which may cause a decrease in
controlled substance use in one state but cause an increase in use in contiguous states without PMPs.42
Collectively, these facts support the need for a national program.

15

PMP administrators are currently

working on a central database for interstate access to PMPs.45
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The West Virginia Schedule II program started in 1995 by the State Board of Pharmacy.15 Now
the prescription monitoring program in West Virginia includes Schedule II through Schedule IV drugs.47
Law enforcement agencies find the program useful for obtaining information to deter or prosecute
doctor shoppers.15
Through a survey of physicians’ attitudes toward using a prescription monitoring system in
southwest Virginia, it has been shown that the majority found the prescription monitoring program to
be useful.16 However, only about 11% actually used the prescription monitoring program data.16 The
majority of physicians felt their prescribing was being monitored through the prescription monitoring
program; furthermore, 23% felt their ability to manage pain for their patients was negatively impacted.
A study of physician attitudes in West Virginia found that 81% of physicians reported using the
Controlled Substance Monitoring Program, but only 22% reported doctor shoppers that they
encountered.48 However, 85% responded that they would report doctor shoppers if there was a law
that protected them.48 PMPs with the right resources have the potential to be useful tools for
healthcare professionals.
Even though prescription monitoring programs theoretically provide a useful tool to help deter
diversion and abuse of prescription drugs, it is important to realize that more research is needed on
their effectiveness. A study by Katz et al. used the PMP in Massachusetts to examine the use of
Schedule II opioid prescriptions and concluded that the PMP could be a useful surveillance tool.29 A
study by Wilsey et al. used the California PMP to examine the utilization of multiple providers for
controlled drug substances.49 They found that as the number of different controlled drug substances
increased, the number of providers used increased as well.49 A study in France using a program from
the general health insurance system found that after making healthcare professionals aware of their
patients who consumed excessive doses, there was a decrease in consumption and a decrease in doctor
shopping.50 More education on utilization and awareness of prescription monitoring programs is
13
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needed so that healthcare professionals can use prescription monitoring programs to their fullest
potential.16
Patients who demand certain prescriptions put physicians in a difficult position.44 PMP data can
be a useful tool when physicians do not have medical records for new patients.44 PMPs assist physicians
in prescribing controlled drug substances to those with legitimate treatment needs by identifying
potential abusers.44
Simoni-Wastila and Tomkinsa conclude in their study that multiple copy prescriptions and
electronic data transfer systems alone are not effective tools for diverting pharmaceuticals.51 They lack
the necessary tools to assess and process data on prescribing and dispensing patterns.51 Thus, an
effective program is needed that identifies and reduces inappropriate prescribing and dispensing while
still allowing legitimate prescribing and dispensing to occur.51

Means of Obtaining Prescription Drugs – Diversion
There are several different channels available for people to divert prescription drugs. A study in
Miami, Florida found that sources of drug abuse were very diverse and included physicians, pharmacists,
a patient’s relatives, doctor shopping, and hospital and pharmacy theft.18 The researchers concluded
that while doctor shopping and internet sources receive much attention with regard to diversion, there
are other factors that deserve attention, including patients, Medicaid recipients and pharmacies.18 A
Canadian abuse study by Fischer et al. found that most diverted drugs came from the medical system or
through friends or partners.20 A presentation by Moric, as reported by Kuehn, also emphasized that
abusers were not getting prescriptions from physicians, but from friends, family and the internet.17 In
2003, two million doses were reported stolen from the supply chain, mostly from pharmacies.21 A study
by Manchikanti et al. found that 42% of patients who were prescribed opioids failed to show opioid
concentrations in their urine,22 which implied that they were selling, giving away, or not using their
prescribed medications. According to Hurwitz, studying the pattern of diversion is important to resolve
14
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unanswered questions including: whether source of drug is from prescriptions; the role of theft or
fraud; limitations of ability to detect diversion; legitimacy of doctor and patient; and whether patient is
giving/selling his/her prescription.23
Not only are the sources of drugs important, but so are the reasons why patients abuse
prescription drugs. A study done in the UK found reasons why patients abused prescription drugs
included selling part of the prescriptions to afford a preferred drug, buying a private prescription, and
supplementing current treatment due to dissatisfaction.52 Anesthesiologists and pain management
physicians were asked to rank a list of 13 aberrant drug taking behaviors.53 Although there was a great
deal of difference among the rankings, there was a common trend to rank illegal behaviors the highest,
followed by alteration of dosage route, and escalation of dosage.53 It is important for healthcare
professionals to have proper education in addiction medicine to deter aberrant drug taking behaviors.53
In order to deter diversion prescribers, drug treatment services, pharmacies, and law enforcement
agencies need to work together.52

Doctor Shopping
Preventing doctor shopping has been a primary focus in reducing prescription drug abuse.
Several studies have examined doctor shopping.7,13,24-27 Two studies examined doctor shopping by using
decedent data.7,13 Researchers found that among all decedents in West Virginia who died of
unintentional pharmaceutical overdoses in 2006 involved diversion (63%) and doctor shopping (21.4%).7
Although diversion was greatest in those aged 18-24 years, doctor shopping was more prevalent in a
slightly older age group (35-44 years and predominantly women).7 Australian decedent records were
examined and showed that there were drug-seeking behaviors identified in the year prior to death.13
These behaviors included doctor-visitation rates, number of different doctors seen, and the rates of
prescriptions peaking the year before death.13 A study by Katz et al. used a prescription monitoring
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program for controlled drug substances to examine trends.29 They found that the greater the number of
prescribers used, there was a greater number of pharmacies used which led to questionable activity.29
A study in France surveyed physicians and examined claims data for buprenorphine
maintenance therapy.27 The investigators found that doctor shopping may not be a deviant behavior,
but may actually be influenced to some extent by physicians.27 The study reported that patients may
doctor shop because they are dissatisfied with inappropriate care and their relationship with their
physician.27 The investigators concluded that physicians’ attitudes toward treating opiate-dependent
patients can influence doctor shopping behaviors.27
Identifying patterns of escalating use, such as an increase in doctor visits, increases in number of
different doctors seen, or an increase in rate of prescriptions may be an opportunity for interventions by
healthcare professionals to perhaps reduce mortality.13 A study in France on high dosage
buprenorphine use found that doctor-shopping could be reduced by adequate indicators on prescription
databases.25 In this way, the effect on legitimate use of buprenorphine would be minimized.25 A
database study of elderly Medicare patients in Quebec found that a single primary care physician
lowered the risk of potentially inappropriate drug combinations across all drug groups.26 The study
concluded that a single primary care physician and a single dispensing pharmacy may prevent
potentially inappropriate drug combinations.26

Pharmacy Shopping
Pharmacy shopping has not been studied very much in the literature.26,28,29 A study by Buurma
defined pharmacy shopping as visiting two or more pharmacies.28 They examined pharmacy shopping
through a Dutch insurance company and found only a small percentage of pharmacy shoppers (10.8%),
of which 98.8% were considered light shoppers.28 Although pharmacy shopping appeared to not be a
major concern in the Netherlands, it may be more of a problem in the United States. A study by Katz et
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al. found a direct correlation between number of prescribers visited and number of pharmacies used,
which often led to questionable activity with Schedule II controlled drug substances.29
A study showed that having a single primary care physician and using a single pharmacy reduce
the odds of a potentially inappropriate drug combination.26 Even though a potentially inappropriate
drug combination is not related to misusing drugs, it could be extrapolated that having a single
pharmacist would increase the probability of identifying aberrant behaviors of drug misuse. Past
literature, research and regulations have primarily focused on physician prescribing and doctor
shopping; perhaps the community pharmacist can play a more significant role in prescription drug
abuse.
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Data Sources

Controlled Substance Monitoring Program
The Controlled Substance Monitoring Program (CSMP) is a database that includes all dispensing
records for Schedule II through Schedule IVcontrolled drug substances (CDS) in the state of West
Virginia. It includes the drug name, drug strength, drug quantity, date filled, the NDC, the DEA number
of the doctor, the DEA number of the pharmacy, the pharmacy zip code, and the patient’s name, date of
birth, and zip code.

Forensic Drug Database
The Forensic Drug Database (FDD) was created as part of the Forensic Drug Information (FDI)
project for use by medical examiners and forensic professionals. The Office of the Chief Medical
Examiner of the State of West Virginia and the West Virginia Center for Drug and Health Information,
which is a service of the West Virginia University School of Pharmacy, are partners in the FDI project.
The FDI project was partly funded by a grant from the National Institute of Justice. The FDD is a
computerized database that allows data about drug-induced or drug-related deaths to be collected and
compiled remotely from anywhere in the world through the Forensic Drug Information website. From
the website, participating medical examiners enter data directly into an internet secured password
protected case entry form. The case entry form has drop down boxes to ease data entry, as well as
areas to write in additional information. The case entry forms are converted into several database
worksheets. The FDD contains case-specific information including decedent characteristics, drugs
detected upon autopsy, pre-existing conditions, cause of death, toxicology and other factors relating to
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drug-induced or drug-related deaths. The main goal of the FDD is to identify patterns and
characteristics related to drug toxicity.

Study Sample
The sample population consisted of subjects who were 18 years or older and who used Schedule
II through Schedule IV controlled drug substances (CDS) in the state of West Virginia from July 1, 2005December 31, 2007. The study samples will be described below by objectives.

Study Sample for Objectives 1-3
The CSMP was the main data source used for objectives 1-3. The FDD dataset was used only to
identify the two comparator groups (living vs. deceased) for objectives 1-3. The FDD was not used as a
primary data source because other drug use information could not be determined for the living group,
such as other drugs used. Subjects who had at least one CDS prescription (Schedule II through Schedule
IV) in the CSMP and were not present in the FDD were assumed to be living subjects. Therefore, the
living group was comprised of these subjects. The deceased group consisted of subjects found in the
CSMP that were also identified in the FDD. Subjects were excluded from the study sample for objectives
1-3 if they were younger than 18 years of age. FDD subjects were not included in the sample population
if they were not found in the CSMP for the dates of the study period.

Study Sample for Objective 4
The FDD was the main data source for objective 4. All subjects who had at least one CDS
detected upon autopsy during the study period were included. The Office of the Chief Medical Examiner
of the State of West Virginia determines from the CSMP data if there was a verified prescription for the
CDS detected upon autopsy over a 60 day window prior to death. This information was used to identify
two comparator groups (verified vs. non-verified) for objective 4.
The verified group consisted of subjects who had a verified prescription in the CSMP for all CDS
(Schedule II through Schedule IV) that were detected upon autopsy. These subjects may or may not
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have died of other drug substances (other prescription drugs (non-controlled drug substances), overthe-counter medications, and/or illicit drugs) which were not examined in the study. The non-verified
group consisted of decedents with at least one CDS detected upon autopsy without a verified
prescription. Each subject in the non-verified group did not have a prescription in the CSMP for at least
one CDS detected upon autopsy. Subjects in the non-verified group may have some, but not all,
prescriptions for the CDS that were detected upon autopsy. These subjects may or may not have died of
other drug substances (other prescription drugs (non-controlled drug substances), over-the-counter
medications, and/or illicit drugs) which were not examined in the study.
Subjects were excluded if they were younger than 18 years of age. Subjects who only had other
prescription drugs (non-controlled drug substances), over-the-counter medications, and/or illicit drugs
detected upon autopsy were excluded because they did not have a CDS detected upon autopsy.

Variables used in Objectives 1-3
Identifying Variables
First and last name and date of birth were used to merge the cases found in the FDD to the
CSMP, but were not used in analyses. First and last name were converted to a unique identifier, and
date of birth was converted to the variable age by the technicians of the CSMP before the researchers
received the data. The doctor’s DEA number was the only variable in the CSMP to identify the doctor.
The doctor’s DEA number was only used to report the number of doctors that a subject visited and was
not used to identify the practitioner. The pharmacy DEA number was used to identify the number of
pharmacies a subject used. The pharmacy DEA number was not used to identify pharmacies in the
study. No unique identifier was used to identify single entities in the results. All results were reported
in aggregate.
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Life Status
Life status was created as a dichotomous variable to identify the living and deceased groups.
(See Study Sample for Objectives 1-3 for a description of these two groups.)

Age
Age is a continuous variable. Date of birth and the last fill date from the CSMP were used to
calculate age before the researchers received the data. Age was used to create the categorical variable
age group. Age was included as a continuous variable in each of the logistic regression equations.

Age Group
Age group was created as a categorical variable, which consists of six groups: 18-24, 25-34, 3544, 45-54, 55-64, and ≥ 65. Age group was used as a variable in the bivariate analysis for each of the
objectives.

Number of Doctors
Number of doctors was defined as the number of doctors who prescribed dispensed CDS
prescriptions per subject for the six months prior to the last CDS prescription dispensed. It was created
with the variables date filled, doctor DEA and unique ID which can all be found from the CSMP. Number
of doctors was used to define doctor shopping.

Doctor Shopping
The variable doctor shopping was based on an article by Hall et al. which defined it as those
who had prescriptions from at least five clinicians in the year preceding death.7 A study by Katz et al.
defined doctor shopping as using four or more prescribers.29 Due to the time span of data available in
the present study, the definition of doctor shopping was operationalized to consider a time period of
six months prior to the last prescription filled. Therefore, doctor shopping was defined with less
doctors per time period then the Hall et al. study. In the present study, doctor shopping is a
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dichotomous variable in which subjects who were dispensed prescriptions from four or more clinicians
over a six month period from the last date filled were considered doctor shoppers; those who visited
less than four clinicians were considered non-doctor shoppers. Four was chosen as a conservative
measure to reduce the propensity of misclassifying an individual as a shopper. The variable number of
doctors was used to define doctor shopping.

Number of Pharmacies
Number of pharmacies was defined as the number of pharmacies that dispensed CDS
prescriptions per subject for the six months prior to the last CDS prescription dispensed. It was created
with the variables date filled, pharmacy DEA, and unique ID which can all be found from the CSMP.
Number of pharmacies was used to define pharmacy shopping.

Pharmacy Shopping
The variable pharmacy shopping was based on an article by Buurma H, et al. which defined
pharmacy shoppers as those subjects who went to two or more pharmacies over a time period of a
year.28 The authors reported that 98% of shoppers were considered light (only using two pharmacies).28
A study by Katz et al. defined pharmacy shopping as using four or more pharmacies.29 In the present
study, pharmacy shopping was defined as a dichotomous variable with those subjects who were
dispensed CDS prescriptions from four or more pharmacies over a six month period from the last date
filled as pharmacy shoppers, and those who had less than four pharmacies dispense CDS prescriptions as
non-pharmacy shoppers. Four was chosen as a conservative measure to reduce the propensity of
misclassifying individual as a shopper. The variable number of pharmacies was used to define pharmacy
shopping.

Date Filled
Date filled was a variable included in the CSMP. It contains the date when the pharmacy
dispensed the CDS prescription. It was used to determine the number of prescriptions dispensed, the
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number of doctors, the number of pharmacies, and the number of different CDS dispensed. Date filled
itself was not used in analysis.

Number of Prescriptions Dispensed
Number of prescriptions dispensed is a variable that was created and was defined as the highest
frequency of the number of prescriptions for CDS dispensed that overlap in a 60 day window for the six
months prior to the last CDS dispensed. It was created with the variables date filled, pharmacy DEA, and
unique ID which can all be found from the CSMP. Number of prescriptions dispensed is a continuous
variable for the logistic regression models in the study. It was also used to create a categorical variable,
number of prescriptions dispensed, which consists of one prescription, two prescriptions, three
prescriptions, and four or more prescriptions.

Drug Name
Drug name was already a variable included in the CSMP. It contains the name of the drugs
dispensed to subjects. The drug names from the CSMP were converted from the NDC by the CSMP
before the researchers received the data. Drug name was used to create the variable number of
different CDS dispensed. Drug name itself as a variable was not used in analysis.

Number of Different CDS Dispensed
Number of different CDS dispensed was created as a categorical variable which consists of single
CDS, two different CDS, and three or more different CDS. Number of different CDS dispensed was
defined as the highest frequency of drug overlap in a 60 day window for the six months prior to the last
CDS prescription dispensed. Number of different CDS dispensed was created by using the variables date
filled, drug name, and unique ID which can all be found from the CSMP.
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Variables used in Objective 4
Unique ID
Unique ID was used to differentiate subjects in the FDD. It was not used to identify subjects in
the results. All results were reported in aggregate.

CDS Prescription Verification
CDS prescription verification was created as a dichotomous variable to identify the verified and
the non-verified groups. (See Study Sample for Objective 4 for a description of these two groups.)

Age
Age is a continuous variable contained in the FDD. Age was used to create the categorical
variable age group. Age was included as a continuous variable in the logistic regression model.

Age Group
Age group was created as a categorical variable, which consists of six groups: 18-24, 25-34, 3544, 45-54, 55-64, and ≥65. Age group was used as a variable in the bivariate analyses.

Drug Name
Drug name was a variable included in the FDD. It contains the name of the drugs detected upon
autopsy. Drug name was used to create the variable number of different CDS dispensed. Drug name
itself as a variable was not used in analysis.

Number of Different CDS Detected at Autopsy
Number of different CDS detected at autopsy was created as a categorical variable which
consists of a single CDS, two different CDS, and three or more different CDS. Number of different CDS
detected at autopsy was defined as the number of different CDS detected upon autopsy. Number of
different CDS at autopsy was created by using the variables drug name and unique ID which can be
found from the FDD.
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Gender
Gender was a variable included in the FDD.
See Appendix A for a code book for the variables.

Analysis of Objectives 1-3
The analysis for the study was conducted using SAS 9.0. Simple descriptive statistics were
conducted to determine frequencies and percentages. Frequencies were reported for the following
variables: life status, age group, doctor shopping, pharmacy shopping, number of different CDS
dispensed, and number of prescriptions dispensed.
Bivariate analyses using the Pearson chi-square statistic were conducted to compare differences
in proportion of subjects classified on shopping status by life status. Among subjects classified as doctor
shoppers, differences in percentages were compared between life status by age group, pharmacy
shopping, number of different CDS dispensed, and number of prescriptions dispensed. The proportion
of subjects who are living and those who are deceased who pharmacy shopped were compared by age
group, doctor shopping, number of different CDS dispensed, and number of prescriptions dispensed.
Logistic regression was conducted to predict the odds of doctor shopping, pharmacy shopping,
and dying related to CDS use. Age, number of different CDS dispensed, and number of prescriptions
dispensed were used as predictor variables for each of the logistic regression equations for doctor
shopping, pharmacy shopping, and dying related to CDS use. The logistic regression equations for
doctor and pharmacy shopping also included life status as a predictor variable. Number of pharmacies
was included in the logistic regression to predict doctor shopping; number of doctors was included in
the logistic regression to predict pharmacy shopping, and both number of doctors and number of
pharmacies as variables were included in the logistic regression equation to predict death related to CDS
use.
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Specific Analysis by Objective
Analysis 1: Frequencies were reported for those who doctor shopped and those that did not further
stratified by life status for age group, pharmacy shopping, number of different CDS dispensed, and
number of prescriptions dispensed.
Analysis 1a: Bivariate analyses (chi-square) were conducted comparing the proportion of subjects who
doctor shopped versus those who did not based on life status.
Analysis 1b: Bivariate analyses (chi-square) were conducted comparing the proportion of subjects
classified as doctor shoppers who are living and who are deceased by age group, pharmacy shopping,
number of different CDS dispensed, and number of prescriptions dispensed.
Analysis 1c: A logistic regression was conducted to predict the odds of doctor shopping controlling for
life status, age, number of different CDS dispensed, number of prescriptions dispensed, and number of
pharmacies.
Analysis 2: Frequencies were reported for those who pharmacy shopped and those who did not further
stratified by life status for age group, doctor shopping, number of different CDS dispensed, and number
of prescriptions dispensed.
Analysis 2a: Bivariate analyses (chi-square) were conducted comparing the proportion of subjects who
pharmacy shopped versus those who did not based on life status.
Analysis 2b: Bivariate analyses (chi-square) were conducted comparing the proportion of subjects
classified as pharmacy shoppers who are living and who are deceased by age group, pharmacy shopping,
number of different CDS dispensed, and number of prescriptions dispensed.
Analysis 2c: A logistic regression was conducted to predict the odds of pharmacy shopping controlling
for life status, age, number of different CDS dispensed, number of prescriptions dispensed, and number
of doctors.
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Analysis 3: A logistic regression was conducted to predict the odds of dying related to the use of CDS
controlling for age, number of different CDS dispensed, number of prescriptions dispensed, number of
pharmacies, and number of doctors.

Analysis of Objective 4
The analysis for the study was conducted using SAS 9.0. Simple descriptive statistics were
conducted to determine frequencies and percentages. Frequencies were reported for the following
variables: CDS prescription verification groups, age group, number of different CDS at autopsy, and
gender.
Bivariate statistics using Pearson chi-square analysis were conducted to compare differences in
proportion of deceased subjects with verified prescriptions versus not having all verified prescriptions by
demographic groups. The proportion of subjects in the verified group and the non-verified group were
compared by age group, number of different CDS at autopsy, and gender.
Logistic regression was conducted to predict the odds of having a CDS prescription for each CDS
detected at autopsy. Age, number of different CDS at autopsy, and gender were used as predictor
variables in the logistic regression equation.

Specific Analysis by Objective
Analysis 4: Frequencies of subjects in the CDS prescription verification groups were conducted for the
following variables: age group, number of different CDS at autopsy, and gender.
Analysis 4a: Bivariate Analyses (chi-square) were conducted comparing the proportion of subjects in the
verified group and the non-verified group by number of different CDS at autopsy and gender.
Analysis 4b: Logistic regression was conducted to predict odds associated with CDS prescription
verification controlling for age, number of different CDS (autopsy), and gender.
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Objectives 1-3

The West Virginia Controlled Substance Monitoring Program contained 1,055,962 subjects from
July 1, 2005 to December 31, 2007. Of these there were 698 subjects who were also found in the
Forensic Drug Database and were therefore considered to be in the deceased group. The remaining 1,
055,264 subjects were considered to be in the living group. Approximately 25.36% of deceased subjects
and 3.61% of living subjects were doctor shoppers. Approximately 17.91% of deceased subjects and
1.31% of living subjects were pharmacy shoppers. Of the living subjects 52.56% had only one
prescription dispensed in the previous six months from the last fill date, whereas 57.88% of deceased
patients had four or more prescriptions dispensed. Approximately 49% of deceased subjects had three
or more different controlled drug substances (CDS); however, 70.99% of living subjects had only a single
CDS in the six months prior to the last fill date. Additional descriptive data are presented in Table 1.
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Table 1
Descriptives by LifeStatus
Living
1,055,264 (99.93)
N (%)

Age Group
18-24
25-34
35-44
45-54
55-64
65+
Doctor Shoppers
Pharmacy Shoppers
Number of Prescriptions Dispensed
1 Prescription
2 Prescriptions
3 Prescriptions
4 or more Prescriptions
Number of Different CDS Dispensed
Single CDS
2 CDS
3 or more CDS

Deceased
698 (0.07)
N (%)

Total
1,055,962
N (%)

102866 (9.75)
172576 (16.35)
182662 (17.31)
201794 (19.12)
167377 (15.86)
227989 (21.60)
38120 (3.61)
13807 (1.31)

59 (8.45)
158(22.64)
192 (27.51)
226 (32.38)
54 (7.74)
9 (1.29)
177 (25.36)
125 (17.91)

102925 (9.75)
172734 (16.36)
182854 (17.32)
202020 (19.13)
167431 (15.86)
227998 (21.59)
38297 (3.63)
13932 (1.32)

554626 (52.56)
210814 (19.98)
141078 (13.37)
148746 (14.10)

118 (16.91)
65 (9.31)
111 (15.90)
404 (57.88)

554744 (52.53)
210879(19.97)
141189 (13.37)
149150 (14.12)

749141 (70.99)
206113 (19.53)
100010 (9.48)

180 (25.79)
176 (25.21)
342 (49.00)

749321 (70.96)
206289 (19.54)
100352 (9.50)

Objective 1: Doctor Shopping
Table 2 summarizes the characteristics and comparisons of Doctor Shopping. Doctor shoppers
had a significantly higher proportion of deceased subjects (0.46%) compared to non-doctor shoppers
(0.05%) (Χ2 = 943.7262, p <.0001). Overall, doctor shoppers had significantly higher proportion of
subjects aged 25-34 (22.41% vs. 16.13%), 35-44 (20.25% vs. 17.21%), and 45-54 (19.89% vs. 19.10%)
compared to non-doctor shoppers who had significantly higher proportion of subjects aged 18-24
(9.79% vs. 8.50%), 55-64 (15.95% vs. 13.38%), and 65+ (21.82% vs. 15.57%) (Χ2 = 1984.1143, p <.0001).
Doctor shoppers had a significantly higher proportion of subjects who pharmacy shopped (20.31%)
compared to non-doctor shoppers (0.60%) (Χ2 = 110072, p <.0001). Doctor shoppers had significantly
higher proportion of subjects who had three prescriptions dispensed (15.27% vs. 13.30%) and four or
more prescriptions dispensed (79.40% vs. 11.67%) compared to non-doctor shoppers who had
significantly higher proportion of subjects who had one prescription dispensed (54.49% vs. 0.52%) and
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two prescriptions dispensed (20.54% vs. 4.81%) (Χ2 = 145026, p <.0001). Doctor shoppers had a
significantly higher proportion of subjects who had two different CDS dispensed (30.51% vs. 19.12%)
and three or more different CDS dispensed (60.48% vs. 7.58%) compared to non-doctor shoppers who
had significantly higher proportion of subjects who only had one CDS dispensed (73.29% vs. 9.00%) (Χ2 =
132620, p <.0001).
Deceased doctor shoppers had significantly higher proportions of subjects aged 25-34 (28.25%
vs. 22.39%), 35-44 (25.42% vs. 20.22%), and 45-54 (32.77% vs. 19.83%) compared to living doctor
shoppers, who had significantly higher proportions of subjects aged 18-24 (8.50% vs. 7.34%), 55-64
(13.42% vs. 5.65%), and 65+ (15.64% vs. 0.56%) (Χ2 = 53.8223, p <.0001). Deceased doctor shoppers had
a significantly higher proportion of subjects who pharmacy shopped (48.02%) compared to living doctor
shoppers (20.18%) (Χ2 = 84.3802, p <.0001). Deceased doctor shoppers had significantly higher
proportion of subjects who had four or more prescriptions dispensed (91.53% vs. 79.34%) compared to
living doctor shoppers, who had significantly higher proportion of subjects who had one prescription
dispensed (0.52% vs. 0%), two prescriptions dispensed (4.82% vs. 1.69%), and three prescriptions
dispensed (15.31% vs. 6.78%) (Χ2 = 16.1979, p <.0001). Deceased doctor shoppers had a significantly
higher proportion of subjects who had three or more different CDS dispensed (81.36% vs. 60.39%)
compared to living doctor shoppers who had significantly higher proportion of subjects who only had
one CDS dispensed (9.03% vs. 2.82%) and two different CDS dispensed (30.58% vs. 15.82%) (Χ2 =
32.9333, p <.0001).
Deceased non-doctor shoppers had significantly higher proportions of subjects aged 25-34
(20.73% vs. 16.13%), 35-44 (28.21% vs. 17.20%), and 45-54 (32.25% vs. 19.10%) compared to living nondoctor shoppers who had significantly higher proportion of subjects aged 18-24 (9.79% vs. 8.83%), 55-64
(15.95% vs. 8.45%), and 65+ (21.83% vs. 1.54%) (Χ2 = 207.8708, p <.0001). Deceased non-doctor
shoppers had a significantly higher proportion of subjects who pharmacy shopped (7.68%) compared to
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living non-doctor shoppers (0.60%) (Χ2 = 433.8380, p <.0001). Deceased non-doctor shoppers had
significantly higher proportion of subjects who had three prescriptions dispensed (19.00% vs. 13.30%)
and four or more prescriptions dispensed (46.45% vs. 11.65%) compared to living non-doctor shoppers,
who had significantly higher proportion of subjects who had one prescription dispensed (54.51% vs.
22.65%) and two prescriptions dispensed (20.55% vs. 11.90%) (Χ2 = 669.1302, p <.0001). Deceased nondoctor shoppers had a significantly higher proportion of subjects who had two different CDS dispensed
(28.41% vs. 19.12%) and three or more different CDS dispensed (38.00% vs. 7.57%) compared to living
non-doctor shoppers, who had significantly higher proportion of subjects who only had one CDS
dispensed (73.31% vs. 33.59%) (Χ2 = 771.5225, p <.0001).
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Table 2
Doctor Shopping Characteristics and Comparisons
2

Χ = 943.7262,
p < .0001
Age Group
2
Χ = 1984.1143,
p < .0001
18-24

Doctor Shoppers
N (%)
Living
Deceased
38120 (99.54)
177 (0.46)
2

2

Χ = 53.8223, p < .0001
3241
(8.50)
8534
(22.39)
7709
(20.22)
7559
(19.83)
5114
(13.42)
5963
(15.64)

25-34
35-44
45-54
55-64
65+
Pharmacy Shopping
2
Χ = 110072, p < .0001
Pharmacy Shoppers

Total
38297

13
(7.34)
50
(28.25)
45
(25.42)
58
(32.77)
10
(5.65)
1
(0.56)

Χ = 207.8708, p < .0001
3254
(8.50)
8584
(22.41)
7754
(20.25)
7617
(19.89)
5124
(13.38)
5964
(15.57)

46
(8.83)
108
(20.73)
147
(28.21)
168
(32.25)
44
(8.45)
8
(1.54)

99671
(9.79)
164150
(16.13)
175100
(17.21)
194403
(19.10)
162307
(15.95)
222034
(21.82)

7778
(20.31)
30519
(79.69)

Χ = 433.8380, p < .0001
6114
40
(0.60)
(7.68)
1011030
481
(99.40)
(92.32)

6154
(0.60)
1011511
(99.40)

199
(0.52)
1841
(4.81)
5849
(15.27)
30408
(79.40)

Χ = 669.1302, p < .0001
554427
118
(54.51)
(22.65)
208976
62
(20.55)
(11.90)
135241
99
(13.30)
(19.00)
118500
242
(11.65)
(46.45)

3448
(9.00)
11686
(30.51)
23163
(60.48)

Χ = 771.5225, p < .0001
745698
175
(73.31)
(33.59)
194455
148
(19.12)
(28.41)
76991
198
(7.57)
(38.00)

2

Χ = 84.3802, p < .0001
7693
85
(20.18)
(48.02)
Non-Pharmacy Shoppers
30427
92
(79.82)
(51.98)
Number of Prescriptions Dispensed
2
2
Χ = 145026, p < .0001
Χ = 16.1979, p = .0010
1 Prescription
199
0
(0.52)
(0.00)
2 Prescriptions
1838
3
(4.82)
(1.69)
3 Prescriptions
5837
12
(15.31)
(6.78)
4 or more Prescriptions
30246
162
(79.34)
(91.53)
Number of Different CDS Dispensed
2
2
Χ = 132620, p < .0001
Χ = 32.9333, p < .0001
1 CDS
3443
5
(9.03)
(2.82)
2 CDS
11658
28
(30.58)
(15.82)
3 or more CDS
23019
144
(60.39)
(81.36)

Non-Doctor Shoppers
N (%)
Living
Deceased
Total
1017144 (99.95) 521 (0.05) 1017665

99625
(9.79)
164042
(16.13)
174953
(17.20)
194235
(19.10)
162263
(15.95)
222026
(21.83)
2

2

554545
(54.49)
209038
(20.54)
135340
(13.30)
118742
(11.67)

2

745873
(73.29)
194603
(19.12)
77189
(7.58)
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The logistic regression results for Doctor Shopping are presented in Table 3. The overall model
with five predictors was significant (p<.001) indicating the equation predicted the odds of a subject
being classified as a doctor shopper. The odds ratios (95% CI) for individual predictors indicated that
those with a higher number of different CDS dispensed had a greater odds of doctor shopping (OR =
1.766; 95% CI = 1.745 – 1.788). Subjects with a greater number of prescriptions dispensed had a greater
odds of doctor shopping (OR = 1.351; 95% CI = 1.343 – 1.359). Subjects who had prescriptions filled at a
greater number of different pharmacies had a greater odds of being a doctor shopper (OR = 2.155; 95%
CI = 2.128 – 2.182). Age showed that older subjects had a lower odds for doctor shopping (OR = 0.979;
95% CI = 0.978 – 0.980). Life status was not a significant predictor of doctor shopping.
Table 3
Logistic Regression Model for Doctor Shopping
Variable
Odds Ratio (95% CI)
Life Status (1=Deceased)
0.959 (0.748, 1.231)
Age
0.979 (0.978, 0.980)
Number of Different CDS Dispensed 1.766 (1.745, 1.788)
Number of Prescriptions Dispensed 1.351 (1.343, 1.359)
Number of Pharmacies
2.155 (2.128, 2.182)
2
Χ (n = 1055962) = 119425.493, p <.0001

p
0.7431
<.0001
<.0001
<.0001
<.0001

Mean (SD):
Age 49.01 (18.68);
Number of Different CDS Dispensed 1.44 (0.84);
Number of Prescriptions Dispensed 2.11 (1.75);
Number of Pharmacies 1.23 (0.62)

Objective 2: Pharmacy Shopping
Table 4 summarizes the characteristics and comparisons for Pharmacy Shopping. Pharmacy
shoppers had a significantly higher proportion of deceased subjects (0.90%) compared to non-pharmacy
shoppers (0.05%) (Χ2 = 1476.3283, p <.0001). Overall, pharmacy shoppers had significantly higher
proportion of subjects aged 25-34 (28.42% vs. 16.20%), 35-44 (23.36% vs. 17.24%), and 45-54 (19.63%
vs. 19.12%) compared to non-pharmacy shoppers who had significantly higher proportion of subjects
aged 18-24 (9.75% vs. 9.50%), 55-64 (15.94% vs. 9.60%), and 65+ (21.75% vs. 9.49%) (Χ2 = 2863.9939, p
<.0001). Pharmacy shoppers had a significantly higher proportion of subjects who doctor shopped
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(55.83%) compared to non-pharmacy shoppers (2.93%) (Χ2 = 110072, p <.0001). Pharmacy shoppers
had a significantly higher proportion of subjects who had four or more prescriptions dispensed (87.27%
vs. 13.15%) compared to non-pharmacy shoppers who had significantly higher proportions of subjects
who had one prescription dispensed (53.23% vs. 0.29%), two prescriptions dispensed (20.20% vs.
2.45%), and three prescriptions dispensed (13.42% vs. 9.98%) (Χ2 = 63110.3184, p <.0001). Pharmacy
shoppers had a significantly higher proportion of subjects who had two different CDS dispensed (25.83%
vs. 19.45%) and three or more different CDS dispensed (65.10% vs. 8.76%) compared to non-pharmacy
shoppers who had significantly higher proportion of subjects who only had one CDS dispensed (71.79%
vs. 9.07%) (Χ2 = 53829.3926, p <.0001).
Deceased pharmacy shoppers had significantly higher proportions of subjects aged 35-44
(29.60% vs. 23.31%) and 45-54 (36.00% vs. 19.48%) compared to living pharmacy shoppers, who had
significantly higher proportions of subjects aged 18-24 (9.52% vs. 6.40%), 25-34 (28.46% vs. 24.00%), 5564 (9.65% vs. 3.20%), and 65+ (9.57% vs. 0.80%)(Χ2 = 36.8703, p <.0001). Deceased pharmacy shoppers
had a significantly higher proportion of subjects who doctor shopped (68.00%) compared to living
pharmacy shoppers (55.72%) (Χ2 = 7.5775, p = .0059). Deceased pharmacy shoppers and living
pharmacy shoppers did not differ significantly in regard to number of prescriptions dispensed (Χ2 =
5.8993, p =.1166). Deceased pharmacy shoppers had a significantly higher proportion of subjects who
had three or more different CDS dispensed (86.40% vs. 64.91%) compared to living pharmacy shoppers,
who had significantly higher proportion of subjects who only had one CDS dispensed (9.14% vs. 1.60%)
and two different CDS dispensed (25.95% vs. 12.00%) (Χ2 = 25.8870, p <.0001).
Deceased non-pharmacy shoppers had significantly higher proportion of subjects aged 25-34
(22.34% vs. 16.19%), 35-44 (27.05% vs. 17.23%), and 45-54 (31.59% vs. 19.12%) compared to living nonpharmacy shoppers who had significantly higher proportion of subjects aged 18-24 (9.75% vs. 8.90%),
55-64 (15.94% vs. 8.73%), and 65+ (21.76% vs. 1.40%) (Χ2 = 220.3250, p <.0001). Deceased non34
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pharmacy shoppers had a significantly higher proportion of subjects who doctor shopped (16.06%)
compared to living non-pharmacy shoppers (2.92%) (Χ2 = 347.4937, p <.0001). Deceased non-pharmacy
shoppers had significantly higher proportions of subjects who had three prescriptions dispensed
(18.32% vs. 13.41%) and four or more prescriptions dispensed (49.91% vs. 13.13%) compared to living
non-pharmacy shoppers, who had significantly higher proportions of subjects with one prescription
dispensed (53.25% vs. 20.59%) and two prescriptions dispensed (20.21% vs. 11.17%) (Χ2 = 737.6915, p
<.0001). Deceased non-pharmacy shoppers had a significantly higher proportion of subjects who had
two different CDS dispensed (28.10% vs. 19.45%) and three or more different CDS dispensed (40.84% vs.
8.74%) compared to living non-pharmacy shoppers, who had significantly higher proportion of subjects
with one CDS dispensed (71.81% vs. 31.06%) (Χ2 = 827.9122, p <.0001).

35

Chapter 4: Results
Table 4
Pharmacy Shopping Characteristics and Comparisons
Pharmacy Shoppers
N (%)
Living
Deceased
Total
13807
125
14197
(99.10)
(0.90)

2

Χ = 1476.3283,
p < .0001
Age Group
2
Χ = 2863.9939,
p < .0001
18-24

2

25-34
35-44
45-54
55-64
65+
Doctor Shopping
2
Χ = 110072,
p < .0001
Doctor Shoppers

2

Χ = 36.8703, p < .0001
1315
(9.52)
3930
(28.46)
3218
(23.31)
2690
(19.48)
1333
(9.65)
1321
(9.57)

8
(6.40)
30
(24.00)
37
(29.60)
45
(36.00)
4
(3.20)
1
(0.80)

Χ = 220.3250, p < .0001
1323
(9.50)
3960
(28.42)
3255
(23.36)
2735
(19.63)
1337
(9.60)
1322
(9.49)

2

101551
(9.75)
168646
(16.19)
179444
(17.23)
199104
(19.12)
166044
(15.94)
226668
(21.76)

51
(8.90)
128
(22.34)
155
(27.05)
181
(31.59)
50
(8.73)
8
(1.40)

101602
(9.75)
168774
(16.20)
179599
(17.24)
199285
(19.12)
166094
(15.94)
226676
(21.75)

2

Χ = 7.5775, p = .0059

7693
85
(55.72)
(68.00)
Non-Doctor Shoppers
6114
40
(44.28)
(32.00)
Number of Prescriptions Dispensed
2
Χ = 63110.3184,
2
Χ = 5.8993, p = .1166
p < .0001
1 Prescription
41
0
(0.30)
(0.00)
2 Prescriptions
340
1
(2.46)
(0.80)
3 Prescriptions
1385
6
(10.03)
(4.80)
4 or more Prescriptions
12041
118
(87.21)
(94.40)
Number of Different CDS Dispensed
2
Χ = 53829.3926,
2
Χ = 25.8870, p < .0001
p < .0001
1 CDS
1262
2
(9.14)
(1.60)
2 CDS
3583
15
(25.95)
(12.00)
3 or more CDS
8962
108
(64.91)
(86.40)

Non-Pharmacy Shoppers
N (%)
Living
Deceased
Total
1041457
573
1042030
(99.95)
(0.05)

Χ = 347.4937, p < .0001
7778
(55.83)
6154
(44.17)

30427
(2.92)
1011030
(97.08)

92
(16.06)
481
(83.94)

30519
(2.93)
1011511
(97.07)

2

Χ = 737.6915, p < .0001
41
(0.29)
341
(2.45)
1391
(9.98)
12159
(87.27)

554585
(53.25)
210474
(20.21)
139693
(13.41)
136705
(13.13)

118
(20.59)
64
(11.17)
105
(18.32)
286
(49.91)

554703
(53.23)
210538
(20.20)
139798
(13.42)
136991
(13.15)

2

Χ = 827.9122, p < .0001
1264
(9.07)
3598
(25.83)
9070
(65.10)

747879
(71.81)
202530
(19.45)
91048
(8.74)

178
(31.06)
161
(28.10)
234
(40.84)

748057
(71.79)
202691
(19.45)
91282
(8.76)

36

Chapter 4: Results
The logistic regression results for Pharmacy Shopping are presented in Table 5. The overall
model with five predictors was significant (p<.001) indicating the equation predicted the odds of a
subject being classified as a pharmacy shopper. The odds ratios (95% CI) for individual predictors
indicated that those with a higher number of different CDS dispensed had a greater odds of pharmacy
shopping (OR = 1.326; 95% CI = 1.304 – 1.349). Subjects with a greater number of prescriptions
dispensed had a greater odds of pharmacy shopping (OR = 1.340; 95% CI = 1.329 – 1.350). Subjects who
visited a greater number of doctors had a greater odds of pharmacy shopping (OR = 1.849; 95% CI =
1.827 – 1.872). Age showed that older subjects had a lower odds for pharmacy shopping (OR = 0.968;
95% CI = 0.967 – 0.970). Deceased subjects had higher odds of pharmacy shopping (OR=2.642; 95% CI =
2.014, 3.466).
Table 5
Logistic Regression Model for Pharmacy Shopping
Variable

Odds Ratio
(95% CI)
Life Status (1=Deceased)
2.642 (2.014, 3.466)
Age
0.968 (0.967, 0.970)
Number of Different CDS Dispensed 1.326 (1.304, 1.349)
Number of Prescriptions Dispensed
1.340 (1.329, 1.350)
Number of Doctors
1.849 (1.827, 1.872)
Χ2 (n = 1055962) = 57157.8322, p <.0001

p
<.0001
<.0001
<.0001
<.0001
<.0001

Mean (SD):
Age 49.01 (18.68);
Number of Different CDS Dispensed 1.44 (0.84);
Number of Prescriptions Dispensed 2.11 (1.75);
Number of Doctors 1.46 (0.92)

Objective 3: Controlled Drug Substance Use Mortality
The logistic regression results for Life Status are presented in Table 6. The overall model with
five predictors was significant (p<.001) indicating the equation predicted the odds of dying related to
CDS use. The odds ratios (95% CI) for individual predictors indicated that those with a greater number
of different CDS dispensed had a higher odds of dying due to CDS use (OR = 1.581; 95% CI = 1.491 –
1.676). Subjects with a greater number of prescriptions dispensed had a greater odds of dying due to
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CDS (OR = 1.110; 95% CI = 1.076 – 1.146). Subjects who used more pharmacies had a higher odds of
dying related to CDS use (OR = 1.288; 95% CI = 1.212 – 1.369). Age showed that older subjects had a
lower odds of dying related to CDS use (OR = 0.967; 95% CI = 0.962 – 0.971). Number of doctors was not
a significant predictor of the odds of dying related to CDS use.
Table 6
Logistic Regression Model for Controlled Drug Substance Mortality
Variable
Age
Number of Different CDS Dispensed
Number of Prescriptions Dispensed
Number of Pharmacies
Number of Doctors
Χ2 (n = 1055962 ) = 1216.1664, p <.0001

Odds Ratio (95% CI)
0.967 (0.962, 0.971)
1.581 (1.491, 1.676)
1.110 (1.076, 1.146)
1.288 (1.212, 1.369)
0.974 (0.932, 1.018)

p
<.0001
<.0001
<.0001
<.0001
.2498

Mean (SD):
Age 49.01 (18.68);
Number of Different CDS Dispensed 1.44 (0.84);
Number of Prescriptions Dispensed 2.11 (1.75);
Number of Pharmacies 1.23 (0.62);
Number of Doctors 1.46 (0.92)

Objective 4: Controlled Drug Substance Prescription Verification
The Forensic Drug Database contained 944 decedents from July 1, 2005 to December 31, 2007
who had at least one CDS detected upon autopsy. The sample was identified exclusively from the FDD
for this objective. The highest proportions of decedents were aged 25-54. Approximately 65% of
decedents were male. The majority of decedents had one or two CDS at autopsy. Additional descriptive
data are presented in Table 7.
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Table 7
Characteristics of Decedents with at Least One Controlled Drug Substance Detected Upon Autopsy
Total
Age Group
18-24
25-34
35-44
45-54
55-64
65+
Gender
Male
Female
Number of Different CDS at Autopsy
1 CDS
2 CDS
3 or more CDS

N (%)
944 (100)
121 (12.82)
235 (24.89
255 (27.01)
267 (28.28)
57 (6.04)
9 (0.95)
617 (65.36)
327 (34.64)
414 (43.86
351 (37.18)
179 (18.96)

Table 8 summarizes the characteristics and comparisons of decedents with regard to CDS
Prescription Verification. Of the 944 decedents, 287 (30.40%) had a verified prescription for all CDS
detected upon autopsy whereas 657 (69.60%) decedents had at least one CDS not verified by a
prescription. Decedents without verification for all their CDS prescriptions detected upon autopsy had
significantly higher proportion of decedents aged 18-24 (16.89% vs. 3.48%), 25-34 (29.68% vs. 13.94%),
and 35-44 (27.55% vs. 25.78%) compared to decedents with verification for all their CDS prescriptions
detected upon autopsy, who had significantly higher proportion of decedents aged 45-54 (44.95% vs.
21.00%), 55-64 (9.76% vs4.41%), and 65+ (2.09% vs. 0.46%) (Χ2 = 103.6627, p <.0001). Decedents
without verification for all their CDS prescriptions detected upon autopsy had a significantly higher
proportion of decedents who were male (68.95%) compared to decedents with verification for all their
CDS prescriptions detected upon autopsy (57.14%) (Χ2 = 12.2987, p <.0001). Decedents without
verification for all their CDS prescriptions detected upon autopsy had a significantly higher proportion of
decedents who had two different CDS (38.96% vs. 33.10%) and three or more different CDS (22.98% vs.
9.76%) compared to decedents with verification for all their CDS prescriptions detected upon autopsy,
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who had significantly higher proportion of decedents who only had one CDS (57.14% vs. 38.05%) (Χ2 =
36.8774, p <.0001).
Table 8
Characteristics and Comparisons of Decedents by Controlled Drug Substance Prescription Verification

Age Group
18-24
25-34
35-44
45-54
55-64
65+
Gender
Male
Female
Number of Different
CDS at Autopsy
1 CDS
2 CDS
3 or more CDS

All Controlled Drug Substance(s)
Verified by a Prescription
N (%)
287 (30.40)
2
Χ = 103.6627, p < .0001
10 (3.48)
40 (13.94)
74 (25.78)
129 (44.95)
28 (9.76)
6 (2.09)
2
Χ = 12.2987, p = .0005
164 (57.14)
123 (42.86)

At Least One Controlled Drug Substance Not
Verified by a Prescription
N (%)
657 (69.60)
111 (16.89)
195 (29.68)
181 (27.55)
138 (21.00)
29 (4.41)
3 (0.46)
453 (68.95)
204 (31.05)

2

Χ = 36.8774, p < .0001
164 (57.14)
95 (33.10)
28 (9.76)

250 (38.05)
256 (38.96)
151 (22.98)

Table 9 summarizes the characteristics and comparisons of decedents with at least one CDS not
verified by a prescription. Of the 657 decedents who had at least one CDS not verified by a prescription,
185 (28.16%) had at least one verified prescription whereas 427 (71.84%) did not have a verified
prescription for all CDS detected at autopsy. Decedents without prescriptions for all their CDS detected
upon autopsy had significantly higher proportion of decedents aged 18-24 (21.61% vs. 4.86%) and 25-34
(30.93% vs. 26.49%) compared to decedents with at least one verified prescription for all their CDS
detected upon autopsy, who had significantly higher proportion of decedents aged 35-44 (32.97% vs.
25.42%), 45-54 (27.57% vs. 18.43%), 55-64 (8.11% vs. 2.97%), and 65+ (0.00% vs. 0.64%) (Χ2 = 40.1107, p
<.0001). Decedents without prescriptions for all their CDS detected upon autopsy and decedents who
had at least one verified prescription for all their CDS detected upon autopsy did not differ significantly
in regard gender (Χ2 = 3.2100, p =.0732). Among decedents who had two or more CDS detected upon
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autopsy, there was a significantly greater proportion that had at least one verified prescription than
those without prescriptions for any of their CDS (Χ2 = 166.1319, p <.0001).
Table 9
Characteristics and Comparisons of Decedents with at Least One Controlled Drug Substance Not Verified
by a Prescription

Age Group
18-24
25-34
35-44
45-54
55-64
65+
Gender
Male
Female
Number of Different
CDS at Autopsy
1 CDS
2 CDS
3 or more CDS

At Least One Verified Controlled Drug
Substance Prescription
N (%)
185 (28.16)
2
Χ = 40.1107, p < .0001
9 (4.86)
49 (26.49)
61 (32.97)
51 (27.57)
15 (8.11)
0 (0.00)
2
Χ = 3.2100, p = .0732
118 (63.78)
67 (36.22)

All Controlled Drug Substances Prescriptions
Were Without Verified Prescriptions
N (%)
472 (71.84)
102 (21.61)
146 (30.93)
120 (25.42)
87 (18.43)
14 (2.97)
3 (0.64)
335 (70.97)
137 (29.03)

2

Χ = 166.1319, p < .0001
0 (0.00)
104 (56.22)
81 (43.78)

250 (52.97)
152 (32.20)
70 (14.83)

The logistic regression results for CDS Prescription Verification are presented in Table 10. The
overall model with three predictors was significant (p<.001) indicating the equation predicted the odds
that a decedent had prescriptions for all CDS detected at autopsy. The odds ratios (95% CI) for
individual predictors indicated that decedents who had a higher number of different CDS at autopsy had
a greater odds of not having a prescription for each CDS detected (OR = 1.842; 95% CI = 1.499 – 2.264).
Males had a greater odds of not having a prescription for each CDS detected than females (OR = 1.667;
95% CI = 1.220 – 2.277). Age showed that older decedents had a lower odds of not having verified
prescriptions for all the CDS detected upon autopsy (OR = 0.933; 95% CI = 0.919 – 0.947).
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Table 10
Logistic Regression Model for Controlled Drug Substance Prescription Verification
Variable
Age
Number of Different CDS at Autopsy
Gender (1=Male)
2
Χ (n =944 ) = 151.2172, p <.0001

Odds Ratio (95% CI)
0.933 (0.919, 0.947)
1.842 (1.499, 2.264)
1.667 (1.220, 2.277)

p

<.0001
<.0001
0.0013

Mean (SD):
Age 38.88 (11.11);
Number of different CDS 1.78 (0.82)
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Chapter 5
Discussion

The results indicated that there is evidence of both doctor shopping and pharmacy shopping in
relation to controlled substances in West Virginia, which was more prominent in deceased than living
subjects. Few living subjects were considered doctor shoppers compared to approximately one-quarter
of deceased subjects who were considered doctor shoppers. The later finding was in agreement to that
from a previous study of the 2006 subset of West Virginia death data where approximately 21% of
deceased prescription drug abusers were considered doctor shoppers.7 Pharmacy shopping followed a
similar trend as seen with doctor shopping. Only about 1% of the living subjects were considered
pharmacy shoppers. This finding is similar to the Buurma et al. study which found that approximately
2% of a living cohort used two or more pharmacies.

28

In contrast, approximately 17% of deceased

subjects were considered pharmacy shoppers. The concern is not only that there is evidence of doctor
shopping and pharmacy shopping, but also how they are related.
Approximately 20% of doctor shoppers were also pharmacy shoppers compared to only 0.6% of
subjects classified as non doctor shoppers. This finding supports a previous finding by Katz et al. that
the greater number of providers used, the number of pharmacies used increases.29 Moreover, a higher
proportion of pharmacy shoppers were also doctor shoppers compared to non pharmacy shoppers. This
finding seems logical in that a patient would need to see more doctors in order to go to more
pharmacies without appearing to be engaging in suspicious behavior, since a patient cannot get a
prescription filled for a controlled drug substance without first seeing a physician. This shows the
significance of communication between healthcare providers and the apparent disconnect evident in
the healthcare system.
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Two results from the study revealed an interesting finding. The number of doctors was not a
significant predictor of the odds of dying related to CDS use, whereas the number of pharmacies was a
significant predictor. Additionally, life status was not a predictor of doctor shopping, but it was for
pharmacy shopping. These results support that pharmacy shopping is an important target in combating
prescription drug abuse. Furthermore, it emphasizes the importance of utilizing prescription monitoring
programs and healthcare professionals working together as a team to combat future doctor and
pharmacy shopping.
Similar patterns emerged for both doctor shopping and pharmacy shopping in regard to
increased utilization of the number of prescriptions dispensed, the number of different controlled drug
substances dispensed, and the number of providers. A large proportion of doctor and pharmacy
shoppers had four or more prescriptions dispensed. However, this may be overestimating doctor and
pharmacy shopping in that living and deceased subjects who have a terminal illness being treated by
multiple physicians may be misclassified as shoppers which would reduce the proportion of living and
deceased shoppers. Regardless of having legitimate reasons for seeing multiple physicians for
treatment of a severe disease, such patients should not be doctor shopping; supporting the importance
of a patient-centered medical home.
In pharmacy shopping there was no difference between living and deceased subjects in number
of prescriptions dispensed. However, a high percentage of both doctor and pharmacy shoppers had
three or more different controlled drug substances dispensed. As well as having increased numbers of
prescriptions and controlled drug substances dispensed, the odds of doctor shopping and pharmacy
shopping increased as the number of pharmacies and the number of doctors increased, respectively.
Furthermore, the number of different controlled drug substances dispensed, the number of different
prescriptions, and the number of pharmacies were all significant predictors of dying.
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These increases in utilization of prescriptions, different controlled drug substances, and
providers were consistent with previous findings. The number of different doctors seen, number of
doctor visitation rates, and the number of prescriptions were found to have peaked the year prior to
death in patients who died of a heroin-related overdose.13 A study using the California Prescription
Monitoring Program also found that with an increase in the number of different controlled drug
substances there was an increase in the number of providers as well. Healthcare professionals should
identify patients with increased utilization rates through prescription monitoring programs if available to
avoid adverse outcomes.
Healthcare professionals should hypervigilantly prescribe/dispense CDS and monitor patients
who have been identified with high utilization rates. In the present study the number of pharmacies,
and not the number of doctors, was a significant predictor of the odds of dying related to CDS use and
provides support for the importance of the role a pharmacist can play working with physicians to
identify at risk patients. Tamblyn et al. found that having a single pharmacist as well as a single
physician reduced potentially inappropriate drug combinations by 32%.26 It is important to note that
patient safety is a shared responsibility among healthcare providers. All healthcare professionals should
work together utilizing prescription monitoring programs when appropriate to prevent the misuse of
controlled drug substances at the same time enhancing patient care.
Among non-shoppers (both doctor and pharmacy), deceased subjects had a higher proportion of
three or more CDS than living subjects. This is a concern because although these subjects were not
considered shoppers they were still dying due to increased use of multiple CDS. This is related to a study
by Bohnert and colleagues.54 They found that higher opioid doses were associated with increased risk of
death.54 This finding along with the findings in the present study that increased number of different CDS
and increased number of prescriptions provide evidence that healthcare professionals need to be
conscious of these risks when prescribing/dispensing to their patients.
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Although the study did not examine the utilization or effectiveness of the Controlled Substance
Monitoring Program, it does support that data captured can be useful to healthcare professionals.
Without the use of an up-to-date prescription monitoring program it would be impossible for healthcare
professionals to accurately identify the utilization markers; currently it is the only way to objectively
identify the use of multiple pharmacies. To receive the full benefit from prescription monitoring
programs, they should be current/real time as well as being at a national level and not just focused on
an individual state. Abusers may travel to contiguous states to obtain controlled drug substances,
especially to states that do not have prescription monitoring programs.42 Creating a valuable
prescription monitoring program might take a great deal of resources (e.g., time, money, personnel) to
keep it running effectively. This cost may be outweighed by the usefulness of the prescription
monitoring program. It can also be used to provide better education and programs to healthcare
professionals, possibly through proactively sharing routine reports of potential doctor/pharmacy
shoppers. Perhaps better counseling, interventions, treatment, and monitoring can be created.
Prescription monitoring programs should not only focus on the patient or the doctor; rather the
pharmacist should be incorporated as a partner to help create a more unified, effective plan.
Prescription monitoring plans have the propensity to save lives if implemented and utilized.
Since approximately 30% of deceased subjects had a verified prescription for all of the
controlled drug substances that were detected upon autopsy, healthcare professionals might have been
able to play a role in preventing their death. Healthcare professionals monitoring and emphasizing to
patients the importance of following their health provider’s instructions appear warranted. Counseling
and re-emphasizing to every patient who receives a controlled drug substance that it is important not to
take non-prescribed drugs or to share his/her drugs with others due to the potential risk for toxicity and
death with those drugs. Unfortunately, around 70% of deceased subjects had at least one controlled
drug substance detected upon autopsy that did not have a verified prescription record for the drug. Of
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these subjects, 30% had two or more controlled drug substances, which means that they are obtaining
at least one of them from the healthcare system where healthcare professionals have a chance to
intervene. However, the other 70% obtained all of their controlled drug substances without
prescriptions. If patients are obtaining controlled drug substances from avenues other than through a
valid visit to a doctor and a pharmacy, it may be impossible to reach out and intervene to a population
that may be more vulnerable for adverse risk.

Limitations
The study is limited by the use of a secondary database that collected variables for intended
purposes other than research. The Controlled Substance Monitoring Program (CSMP) database does
not capture how subjects paid for their controlled drug substances (e.g., type of insurance, cash), the
subjects’ medical conditions the controlled drug substance is treating, any medical records for the
subjects, or gender. This limits the amount of questions a researcher can answer using the database.
The CSMP only captures data on prescriptions that have been filled for a controlled drug substance
(Schedule II through Schedule IV).47 From January 1, 2006, Schedule V pseudoephedrine products were
required to be reported to the CSMP.47 Schedule V pseudoephedrine data were not included in the
study, because it could be purchased without a prescription. The data do not ensure that the patient
actually picked up the medication and therefore may slightly overestimate doctor and pharmacy
shopping. Only prescription drugs dispensed in the state of West Virginia are reported in the CSMP. If a
patient lives close to a bordering state he/she may have his/her prescriptions filled in a neighboring
state which may underestimate doctor and pharmacy shopping. Government facilities (e.g., VA
hospitals) and inpatient hospitals do not report data to the CSMP, which could also underestimate
doctor and pharmacy shopping.
The CSMP might have limited the estimate of doctor shopping for two different reasons. First,
living and deceased subjects may have been misclassified as doctor shoppers when actually they had a
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severe disease being treated by multiple physicians. Thus, removing these patients would lower the
proportion of true doctor shoppers in both the living and deceased groups. Therefore, the true effect
size of the difference in shopping rates between the living and deceased groups cannot be determined
in this study because of potential misclassification.
Secondly, doctor shopping may have been overestimated because patients may see more than
one doctor within the same clinic or practice, causing them to appear to be doctor shoppers even when
they are not. Doctor shopping may also be overestimated because a patient may seek out several
physicians in an attempt to adequately treat their pain. However, even if there is a team of physicians,
either within or outside the same clinic (e.g. a primary care physician, a disease specialist, a pain
specialist, and perhaps an addiction specialist) treatment should be coordinated with only one physician
prescribing the pain medications. Pharmacists can utilize prescription monitoring programs to monitor
multiple controlled drug substance use and communicate with involved prescribers to ensure they are
aware of the other prescriptions.
Pharmacy shopping may be overestimated because some patients may get their prescriptions
filled at different pharmacies for legitimate reasons, such as convenience, the pharmacy they usually go
to may not have the medication in stock, or perhaps their insurance changed and they can only go to
certain pharmacies to get their prescriptions. Pharmacy shopping may also be overestimated because
patients may go to two different pharmacies in the same chain that share patient profiles, essentially
meaning the patient is going to one pharmacy although the CSMP would record it as two different
pharmacy DEA numbers.
The conservative definitions (i.e., equal to or greater than four doctors/pharmacies over a six
month period) of doctor/pharmacy shopping should minimize the aforementioned reasons for possible
overestimations of both doctor shopping and pharmacy shopping. The conservative definitions might in
fact reflect an underestimate of both doctor and pharmacy shopping. Patients may also doctor and
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pharmacy shop for non-controlled drug substance abused drugs (e.g., Flexeril®) not captured by the
CSMP. A more liberal definition for both doctor/pharmacy shopping as seeing three or more
doctors/pharmacies in a six month period produced robust results; since the findings were similar (data
not included) the more conservative definitions were used.
The study did not examine the quantity or strength of the medications. Therefore, three
prescriptions for Xanax with a 10-day supply would appear the same as three prescriptions for a 30-day
supply. Both would be counted as three prescriptions and one controlled drug substance dispensed.
The generalizability of the study may be limited because only West Virginia data were used.
Previous research has shown that West Virginia has a higher rate of prescription drug abuse than the
national average.7,12 Finally, there was no way to track in the CSMP if patients in the living group were
taking additional controlled drug substances for which they do not have a prescription and/or illegal
drug use; therefore, the results from the study should not be extrapolated to other drug categories such
as non-controlled prescriptions, over-the-counter medications and/or illegal drugs beyond the use of
controlled drug substances.
The time to resuscitation is a major limitation of studying unintentional drug overdoses from a
database. A subject’s personal behaviors and habits, health status, body state especially obesity, and
the distance to healthcare services are important factors in regards to resuscitation. These factors are
not contained in the FDD or the CSMP.

Future Research
Additional studies are needed to explore other unanswered questions about the use of
prescription monitoring programs. A previous study examined physicians’ attitudes towards a
prescription monitoring program,16 but there is still a need to examine utilization of prescription
monitoring programs by pharmacists. Additional studies are needed to explore other unanswered
questions about the use/abuse of controlled drug substances including whether a certain pattern exists
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for specific strengths and days supply for certain drugs. This information would help prescription
monitoring programs target certain patterns and identify potential patients that could benefit from
intervention by a healthcare provider.
While the study only used subjects from West Virginia, future research should examine a
broader sample that would include all states that have prescription monitoring programs. Also the FDD
is a potential resource for future studies, especially if more states contribute drug-induced and drugrelated death information. As data collection grows over the years in these relatively new electronic
databases, trend analysis on controlled drug substance use and drug death could be a valuable research
avenue.
Future studies should continue to examine doctor and pharmacy shopping from a healthcare
professional’s perspective. It is important to include a well representative sample of community
pharmacists. As the last healthcare professional that patients see before obtaining their medications,
pharmacists should be surveyed to help identify needed resources required to intervene with patients
who have a potential to doctor and pharmacy shop.

Conclusion
In conclusion, there is evidence of doctor shopping and pharmacy shopping for controlled drug
substances in West Virginia. One-fifth of doctor shoppers were also pharmacy shoppers, and 55% of
pharmacy shoppers were also doctor shoppers. Factors that predicted odds of being a shopper
included: 1) number of prescriptions dispensed; 2) number of different controlled drug substances
dispensed; 3) number of physicians visited; and 4) number of pharmacies visited. Pharmacists should
play a role in intervening with patients who display these risk factors, as prescription drug
diversion/abuse prevention should not be placed on prescribers exclusively. Pharmacists as well as
physicians may rely on a prescription monitoring program to identify pharmacy shoppers. An
intervention by the pharmacist is important because almost a third of deceased subjects had a verifiable
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prescription for all of their controlled drug substances detected upon autopsy. Utilization of a
prescription monitoring program by healthcare professionals as an integrated tool for tracking the
prescribing and dispensing of controlled drug substances, as well as its propensity to prevent druginduced and drug related deaths, should be considered.
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Objective 1-3

Identifying Variables
First & Last Name  Unique ID
Date of Birth  Age
Doctor DEA
Pharmacy DEA
Life Status

Living = 0
Deceased= 1

Age

= calculated from the date of birth and last fill date in the CSMP; found in the FDD as the age at death

Age Group
18-24 = 0
25-34 = 1
35-44 = 2
45-54 = 3
55-64 = 4
≥65 = 5

Number of Doctors

= number of doctors that prescribed CDS prescriptions per subject for the 6 months prior to the last CDS
prescription dispensed

Doctor Shopping

NoDrShop (<4 clincians/last 6 months) = 0
DrShop (≥4 clinicians/last 6 months) = 1

Number of Pharmacies

= number of pharmacies that dispensed CDS prescriptions per subject for the 6 months prior to the last
CDS prescription dispensed

Pharmacy Shopping

NoPhShop (<4 pharmacies/last 6 months) = 0
PhShop (≥4 pharmacies/last 6 months) = 1

Date Filled

= the dates when the pharmacy dispensed the controlled drug substance prescription
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Number of Prescriptions Dispensed

= the highest frequency of the number of controlled drug substance prescriptions dispensed that
overlap in a 60 day window for the 6 months prior to the last controlled drug substance dispensed
Number of Prescriptions Dispensed Group
1 Prescription = 0
2 Prescriptions= 1
3 Prescriptions = 2
4 or more Prescriptions = 3

Drug Name

= name of drug dispensed

Number of Different CDS Dispensed
Single CDS = 0
2 different CDS = 1
3 or more different CDS =2

Objective 4
Unique ID

CDS prescription Verification
Verified = 0
Non-verified = 1

Age

=the age at death

Age Group
18-24 = 0
25-34 = 1
35-44 = 2
45-54 = 3
55-64 = 4
≥65 = 5

Drug Name

= name of drug detected upon autopsy

Number of Different CDS Detected at Autopsy
Single CDS = 0
2 different CDS = 1
3 or more different CDS =2

Gender

Male = 1
Female = 0
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